PharmAla Biotech Holdings Inc., a biotechnology leader in the research, development, and manufacturing of novel MDXX class molecules, is thrilled to announce the filing of its patent on the composition of matter of PharmAla-1.
The novel drug development pipeline has seen a rapid advancement this year, placing PharmAla’s ALA family on the brink of clinical trials. This Composition of Matter patent on the Novel Chemical Entity (NCE) PharmAla-1 solidifies the firm’s standing as a premier designer of Central Nervous System (CNS) pharmaceutical treatments.
PharmAla-1 is set to revolutionize the way we approach mental health treatments, combining the potency of classical psychedelics with the pro-social effects of MDXX compounds. According to the CEO of PharmAla Biotech, Nick Kadysh, the potential of PharmAla-1 has been studied, revealing that it requires less of the drug to experience the desired therapeutic effects,than traditional drugs. Its computational chemistry also shows that the molecule has much stronger serotonin binding than MDMA, making it a much more effective choice for mental health treatments.
PharmAla Biotech, in partnership with the University of Windsor, has unlocked a new drug discovery approach through computational in-silico modelling, leading to the discovery of PharmAla-1. This breakthrough has been made possible through a grant from the Ontario Centres of Innovation.
PharmAla-1 is the inaugural molecule of PharmAla’s comprehensive computational drug development pipeline. In addition, PharmAla has successfully developed and patented ALA and ABA drug derivatives through traditional drug discovery methods.
PharmAla Biotech’s drug discovery ethos of regulatory excellence and cutting-edge science has come together in an exciting way with PharmAla-1. Compared to traditional MDXX compounds, this non-controlled drug shows promising safety pharmacology profiles, allowing for faster regulatory development.
Modeling suggests that it could be a neuroplasticity-inducing compound, containing potential receptor binding profiles indicative of a bridge between substituted phenethylamine-based MDXX molecules and classical 5-HT2 agonists of classical Psychedelics.
Therefore, PharmAla-1 could represent a valuable addition to the Psychiatric pharmacopoeia, with its potential to provide a useful tool in the expanding PharmAla IP portfolio.
PharmAla is thrilled to present its groundbreaking research, featuring the incredible potential of PharmAla-1, ALA, and ABA families, at some of the leading pharmaceutical conferences in Fall 2023. Join us to learn more about how our animal model research is making great strides in advancing healthcare solutions!
Publication in Psychedelic Medicine
We are thrilled to announce that our review article, “Balancing therapeutic efficacy and safety of MDMA and novel MDXX analogues as novel treatments for autism spectrum disorder,” has been accepted for publication by Psychedelic Medicine. This article delves into the potential use of MDMA and other analogues as therapies for autism spectrum disorder, analyzing the risks and benefits of this exciting new avenue of treatment.
Millions of people around the world are affected by Autism Spectrum Disorder (ASD). With no approved pharmacological treatments targeting the global symptoms of the disorder, there is an urgent need for an effective remedy.
PharmAla Biotech’s review article addresses the possibility of using MDMA-like drugs to alleviate social anxiety and avoidance often experienced by those with ASD. This could ultimately lead to increased social interactions and improved daily functioning.
Exploring the potential of MDMA and its analogues as treatments for autism spectrum disorder, scientists are delving into the nuanced pharmacology of these entactogens, uncovering their drug-binding sites, metabolic enzymes, and chemical structure-activity relationships. In this pursuit, they are striving to find a balance between therapeutic efficacy and safety for a promising new form of therapy.
The potential of MDMA and its analogues to provide therapeutic value has long been known, but was unfortunately suppressed due to the abuse-related and toxic side effects. However, through a better comprehension of the complex pharmacology of these substances, scientists have been able to design drug formats and formulations that reduce the danger of detrimental effects while sustaining whatever beneficial effects they may have.
In this review, we take a look at how this progress is being applied in the context of treating autism spectrum disorder, and seek to identify further battlegrounds for future research.
At PharmAla Biotech, our commitment to scientific excellence and innovative research is pushing the boundaries of psychedelic medicine in pursuit of improving the lives of those affected by mental health ailments.
With that goal in mind, we are exploring the therapeutic potential of MDMA-like compounds to offer new hope for individuals with autism spectrum disorder and their families. We are eager to prove our ability to do this by moving these molecules into the clinic, which is our next step with our lead molecule, ALA-002, in partnership with the University of Sydney.
PharmAla Biotech Holdings Inc. (CSE: MDMA) is shaking up the biotechnology world by researching, developing, and manufacturing clinical-grade MDMA. This innovative company, the first publicly-traded firm to do so, is tackling the global backlog of generic MDMA to enable clinical trials.
Not stopping there, PharmAla is forging ahead with novel drugs in the same class and has already completed proof-of-concept research on their IP families. Knowing that true success requires excellent relationships with regulators, PharmAla proudly makes regulatory-first decisions.